Cetirizine and Levocetirine in Pediatric Allergic Rhinitis and Chronic Urticaria

Indications & Regulatory Approval

The American Academy of Allergy, Asthma & Immunology (AAAAI) guidelines endorse second‑generation antihistamines cetirizine and levocetirizine as safe and effective first‑line therapies for pediatric allergic rhinitis (both seasonal and perennial) and chronic idiopathic urticaria. [1][2]3
Both agents are approved for use beginning at 6 months of age, with age‑specific dosing regimens (see Dosing section). 3

Cetirizine – 2.5 mg once daily for infants 6 months – < 2 years; 2.5 mg once or twice daily (max 5 mg/day) for children 2‑5 years; 5‑10 mg once daily for ages 6‑11 years; 10 mg once daily for ≥ 12 years. 3
Levocetirizine – 1.25 mg once daily in the evening for children 6 months – < 6 years; 2.5 mg once daily in the evening for ages 6‑11 years; 5 mg once daily in the evening for ≥ 12 years. 3

The AAAAI guidelines state that, among newer non‑sedating antihistamines, no single agent has demonstrated a consistently superior overall response rate in children. [6][7][8][9]
Comparative pediatric data suggest cetirizine may provide greater symptom relief than levocetirizine in some cases, supporting its use when an inadequate response to standard dosing is observed. 7
Both cetirizine and levocetirizine effectively control the four principal symptoms of allergic rhinitis—sneezing, itching, rhinorrhea, and nasal congestion. 1

Large‑scale safety assessments in the AAAAI guidelines confirm that second‑generation antihistamines, including cetirizine and levocetirizine, have excellent tolerability in young children, contrasting with first‑generation agents and OTC cough/cold products that should be avoided < 6 years. [1][2][4][5]
Sedation risk: Cetirizine at the approved 10 mg dose produces mild drowsiness in 13.7 % of patients ≥ 12 years versus 6.3 % with placebo; higher doses may impair psychomotor performance. [6][7]9
Both agents carry a comparable overall sedation risk; clinicians should counsel families about possible drowsiness, especially in low‑weight children where mg/kg exposure is higher. [6][7]8
Non‑sedating alternatives (fexofenadine, loratadine, desloratadine) are recommended when sedation is a primary concern, as fexofenadine has demonstrated no sedation even at supra‑therapeutic doses. [6][7][8][9]

First‑line therapy: Either cetirizine or levocetirizine may be selected for pediatric allergic rhinitis or chronic urticaria, following guideline recommendations. [1][2][4][5]
Dosing considerations: Apply the age‑appropriate regimens outlined above; both drugs are approved from 6 months onward. 3
Sedation management: If sedation is problematic, consider switching to a truly non‑sedating antihistamine (e.g., fexofenadine). [6][7][8][9]
Cost & accessibility: Cetirizine is available over‑the‑counter, often making it more cost‑effective; levocetirizine typically requires a prescription. 3

Renal impairment: Both cetirizine and levocetirizine are contraindicated in children with significant kidney disease per FDA labeling. [no citation – omitted]
Weight‑based dosing: In low‑body‑mass patients, standard age‑based doses may result in higher mg/kg exposure, increasing the likelihood of drowsiness and performance impairment. [6][7]
Indication limitation: These antihistamines are indicated solely for allergic conditions and should not be used for cough or cold symptoms, where antihistamine‑decongestant combinations have shown no efficacy in children. [1][2][4][5]